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Background: 25-hydroxycholesterol (25-HC) is one of the oxysterols, which are oxidized derivatives of cholesterol,
and has been reported to be involved in the pathogenesis of atherosclerosis and Alzheimer’s disease. In lung, the
possible involvement of 25-HC in airway diseases has been revealed. In the present study, we examined whether
25-HC affects the release of cytokines and also modulates the responses of toll-like receptor 3 (TLR3) in airway
epithelial cells.
Methods: The effect of 25-HC on the release of cytokines from primary human bronchial epithelial cells after
stimulation with or without polyinosine-polycytidylic acid [poly(I:C)], a ligand for TLR3, and the signal transduction
were examined.
Results: 25-HC significantly potentiated the release of interleukin-8 (IL-8) and IL-6 from the cells. This effect was
more potent compared with that of other oxysterols, 22-HC and 27-HC. GW3965 and TO901317, synthetic agonists
of liver X receptors that are receptors for oxysterols, did not augment the IL-8 release. 25-HC enhanced the nuclear
factor-kappa B (NF-κB) DNA binding activity and translocation of phosphorylated c-Jun into the nucleus. The release
of IL-8 was inhibited by the NF-κB inhibitor, caffeic acid phenethyl ester (CAPE), an inhibitor of nuclear factor
kappa-B alpha (IκBα) inhibitor, BAY 11–7085, and an inhibitor of nuclear factor kappa-B kinase-2 (IKK-2) inhibitor,
SC-514, but not by a c-Jun N-terminal kinase (JNK) inhibitory peptide, L-JNKi1. 25-HC significantly potentiated IL-8
release in poly(I:C)-treated cells and the augmentation was inhibited by CAPE, BAY 11–7085, and SC-514.
Furthermore, 25-HC potentiated the translocation of interferon regulatory factor 3 into the nucleus and the release
of interferon-beta (IFN-β) in poly(I:C)-treated cells.
Conclusions: These data demonstrated that 25-HC augments the release of IL-8 and IL-6 via NF-κB signalling
pathway and enhances the release of IL-8 and IFN-β after stimulation of TLR3 in airway epithelial cells. 25-HC may
be involved in the neutrophilic airway inflammation through the stimulant effect of IL-8 and IL-6 release and also
potentiate the TLR3-mediated innate immunity in airway diseases.
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25-hydroxycholesterol (25-HC) is one of the oxysterols,
which are oxidized derivatives of cholesterol and are
important modulators of cholesterol metabolism [1].
25-HC is produced from cholesterol by cholesterol
25-hydroxylase, which is detected in several cell types in-
cluding macrophages [2]. 25-HC has been reported to be
mainly involved in the pathogenesis of atherosclerosis [3]
and Alzheimer’s disease [4] affecting various aspects such
as cytokine release [5] and the imbalance between matrix
metalloproteinases and specific tissue inhibitors of metal-
loproteinases [6] in macrophage lineage cells. These
effects have been reported to be mediated by one type of
nuclear receptors, liver X receptors [7] or via signalling
pathways including nuclear factor-kappa B (NF-κB) [8,9],
c-Jun N-terminal kinase (JNK) and mitogenic extracellular
kinase/extracellular signal-regulated kinase1/2 (MEK/
ERK1/2) [5,10]. In addition, a recent report demonstrated
that 25-HC also affects immune systems via the suppres-
sion of immunoglobulin A production [2].
In lung, the possible involvement of 25-HC in airway
diseases has been revealed. Recently, we demonstrated
that the expression of cholesterol 25-hydroxylase in
alveolar macrophages and pneumocytes in human lung
tissues and the level of 25-HC in sputum from patients
with chronic obstructive pulmonary disease (COPD) are
increased compared to non-smoker control subjects [11].
In addition, the concentrations of 25-HC in sputum were
significantly correlated with the sputum interleukin-8
(IL-8) levels and neutrophil counts [11]. These results sug-
gest that 25-HC might modulate neutrophilic airway
inflammation in lung diseases.
Airway epithelial cells are one of the key cells in the
pathogenesis of airway diseases through the release of
proinflammatory cytokines including IL-1β, IL-6 and
neutrophil chemotactic factor, IL-8 after stimulation
such as by allergen and oxidant contained in air pollu-
tion [12]. In addition, airway epithelial cells are one of
the first defenses against inhaled microorganisms via the
innate immune systems, including toll-like receptors
(TLRs), through recognizing pathogen-associated mo-
lecular patterns [13]. Virus infections are a major cause
of exacerbations of the airway diseases that are charac-
terized by the accumulation of neutrophils in the
airways, and preventing such exacerbations is necessary
to inhibit the progression of the disease [14,15]. Re-
cently, TLR3 has been demonstrated to react to double-
stranded RNA (dsRNA) and to be involved in the im-
mune responses after viral infections [13]. Activation of
TLR3 stimulates the production of inflammatory cyto-
kines including IL-8 and type I interferons (IFNs) via
NF-κB and interferon regulatory factor 3 (IRF3) pathway
[13] and the enhancement of TLR3 response has been
demonstrated in airway diseases [16,17].In airway diseases, including COPD, it is known that
there is overproduction of 25-HC in the airways that is
correlated with neutrophilia, and that the airway epithelial
cells have an important role in the pathogenesis of the
diseases and in the exacerbations. However, the effects of
25-HC on airway epithelial cells and in modulating the
TLR3 response, which could be involved in the mechan-
ism of the exacerbation, have not been elucidated. The
present study, therefore, was designed to determine the
following: 1) whether 25-HC could affect the cytokine
release including IL-8 in human airway epithelial cells;
2) which signal pathway is involved in this mechanism;
3) whether 25-HC could affect the TLR3-mediated IL-8
and IFN-β release in human airway epithelial cells using
polyinosine-polycytidylic acid [poly(I:C)], a synthetic ana-
log of viral dsRNA and a ligand of TLR3.
Materials and methods
Materials
Commercially available reagents were obtained as follows:
poly(I:C) was purchased from Amersham Biosciences
(Piscataway, NJ); caffeic acid phenethyl ester (CAPE), BAY
11–7085 and SC-514 were purchased from Calbiochem
(La Jolla, CA); serum-free Keratinocyte Basal Medium and
its supplement including recombinant epidermal growth
factor and bovine pituitary extract were purchased from
Invitrogen Life Technologies (Grand Island, NY); 22(R)-
HC, 25-HC, GW3965, TO901317, SB203580, U0126,
HBSS, BSA, phenylmethylsulfonyl fluoride, aprotinin,
leupeptin, thiazolyl blue tetrazolium (MTT) and dimethyl
sulphoxide (DMSO) were purchased from Sigma Aldrich,
Inc. (St. Louis, MO). 27-HC and L-JNKi1 were purchased
from Avanti Polar Lipids, Inc.(Alabaster, AL) and Enzo
Life Sciences, Inc. (Exeter, UK), respectively.
Preparation of epithelial cells
Four strains of primary human bronchial epithelial cells
(HBEpC) from normal subjects were purchased from Cell
Aplications Inc. (San Diego, CA) and ScienCell research
laboratories (Carlsbad, CA). HBEpC (passages 3–6) were
cultured in serum-free Keratinocyte Basal Medium sup-
plemented with 10 ng/ml recombinant epidermal growth
factor and 30 μg/ml bovine pituitary extract. Cells were
cultured at 37°C in a humidified atmosphere of 5% CO2
and passaged. Cells were routinely grown to 80% conflu-
ence and growth was arrested overnight prior to the ex-
perimental procedures by transfer to growth factor-free
media [17]. Cells were cultured in 96-well plates for inves-
tigating the effect of 25-HC or other ligand-induced cyto-
kine release. To investigate the effect of 25-HC or other
ligand-induced cytokine release, the supernatants were
harvested at 24 h after the treatment and stored at −80°C
until the measurement. To estimate the effect of 25-HC
on the poly(I:C)-induced cytokine release, 25-HC was
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poly(I:C). To evaluate the effects of CAPE, BAY 11–7085,
SC-514, SB203580, U0126 or L-JNKi1, these drugs were
added to the media at various concentrations, 30 min or
60 min (BAY 11–7085 and SC-514) prior to 25-HC or
poly(I:C) treatment.
Cell viability assay
The cell viability was estimated by thiazolyl blue tetrazo-
lium (MTT) assay according to previous study [17].
Measurement of cytokines
The amounts of IL-8 and IFN-β were measured in the
supernatants using Enzyme-Linked Immunosorbent Assay
(ELISA) Kit (R&D Systems, Abingdon, UK and Thermo
Fisher Scientific Inc., Rockford, IL). The amounts of IL-6
and IL-1β were measured in the supernatants using
Cytometric Bead Array kit (BD Biosciences, San Jose, CA)
according to the manufacturer’s instructions.
NF-κB p65 DNA binding activity
To assess NF-κB p65 DNA binding activity, the nuclear
fraction was obtained after 0–120 min incubation with
poly(I:C) or vehicle and evaluated by an NF-κB p65 tran-
scription factor assay kit, which is based on the method
of ELISA (Cayman Chemical Company, Ann Arbor, MI)
according to the manufacturer’s instructions [17].
Detection of pc-Jun and IRF-3 by nuclear extraction and
immunoblotting
Cells were treated with 10 μg/ml 25-HC for 0–120 min.
After washing with HBSS, cells were homogenized in cell
lysis buffer to obtain the nuclear fraction. Samples were
separated by electrophoresis and blotted on a PVDF mem-
brane. The following antibodies were used for detection of
the target proteins: mouse monoclonal anti-pc-Jun anti-
body (1:200 dilution; Santa Cruz Biotechnology), rabbit
polyclonal anti–IRF-3 antibody (1:1000 dilution; Santa
Cruz Biotechnology), or mouse monoclonal anti-lamin
A/C antibody (1:750 dilution; Santa Cruz Biotechnology).
Appropriate peroxidase-conjugated secondary antibodies
were used. Binding antibodies were detected using ECL-
plus (Amersham Biosciences, Buckinghamshire, UK) and
visualized with a chemiluminescence imaging system
(Luminocapture AE6955, Atto Co., Tokyo, Japan). Each
band intensity was quantified by densitometry (Image J,
NIH, Frederick, MD).
Detection of TLR3 expression
Cells were treated with 10 μg/ml poly(I:C) in the pres-
ence or absence of 10 μM 25-HC for 24 h. After washing
with HBSS, cells were homogenized in cell lysis buffer
(0.05% Triton X, 35 mM Tris–HCl, pH 7.4, 0.4 mM
EGTA, 10 mM MgCl2, 1 μM phenylmethylsulfonylfluoride, 100 μg/ml aprotinin and 1 μg/ml leupeptin) at
4°C. Samples were solubilized in SDS-PAGE sample buf-
fer. Equal amounts of protein were separated by electro-
phoresis on 15% SDS polyacrylamide gels and blotted on
a PVDF membrane. Mouse monoclonal anti-TLR3 anti-
body (1:250 dilution; Imgenex Corporation, San Diego,
CA) or mouse monoclonal anti-β-actin antibody
(1:10000 dilution; Sigma, St. Louis, MO) were used for
the detection of target proteins. Peroxidase-conjugated
appropriate secondary antibodies were used. The follow-
ing detection and visualization procedures were per-
formed the same as for NF-κB immunoblotting.Statistical analysis
Data were expressed as means ± SEM. GraphPad Prism
(GraphPad Software Inc., San Diego, CA) was used to
perform all statistical tests. Experiments with multiple
comparisons were evaluated by one way analysis of vari-
ance (ANOVA) followed by Bonferroni's test or Dunnett's
test to adjust for multiple comparisons. An unpaired Stu-
dent's t-test was used for single comparisons. Probability
values of less than 0.05 were considered significant.Results
Effect of oxysterols or liver X receptor ligands on IL-8
release in HBEpC
To confirm whether 25-HC affects the function of air-
way epithelial cells, we investigated the effect of 25-HC
on the release of IL-8 from HBEpC. 25-HC significantly
increased the release of IL-8 from the cells in a time-
and concentration-dependent manner (Figure 1A-B).
Next, we compared the effect of 25-HC with other oxy-
sterols, 22-HC, which is a potent activator of liver X
receptors [18-20], and 27-HC, which is the most abun-
dant oxysterol in the bloodstream [21]. 22-HC and
27-HC also increased the release of IL-8 from the epithe-
lial cells (Figure 1C-D). This augmented effect by 22-HC
and 27-HC was not detected at the concentration of 10-6
M compared with that of 25-HC, suggesting that the aug-
mented effect of 22-HC and 27-HC on IL-8 release was
less potent compared with that of 25-HC. Concerning the
effect of oxysterols on the cell viability, the cell viability
was decreased by about 20 percent only at 10-4 M of
25-HC. On the other hand, both 22-HC and 27-HC
decreased the cell viability at lower concentrations from
10-6 M to 10-4 M than did 25-HC.
Previously, 25-HC has been reported to react via liver X
receptors [7]. To confirm whether the effect of 25-HC on
IL-8 release is mediated via liver X receptors, we used
agonists of liver X receptors, GW3965 and TO901317.
However, neither GW3965 nor TO901317 augmented the
release of IL-8 (Figure 1E-F), and TO901317 significantly













































































































































































Figure 1 Effect of oxysterols and liver X receptor ligands on IL-8 release in HBEpC. (A) Cells were treated with 10-5 M of
25-hydroxycholesterol (25-HC). At various time points after the incubation, supernatants were harvested and assayed for IL-8 by ELISA. (B-F) Cells
were treated with various concentrations of 25-HC (B), 22-hydroxycholesterol (22-HC) (C), 27-hydroxycholesterol (27-HC) (D), liver X receptor
ligands, GW3965 (E), or TO901317 (F). After 24 h, supernatants were harvested and assayed for IL-8. Inserted figures show the effects of
hydroxycholesterols and liver X receptor ligands on cell viability. Cells were incubated with various concentrations of 25-HC (B), 22-HC (C), 27-HC
(D), GW3965 (E), TO901317 (F) or vehicle for 24 h. Cell viability was assessed by MTT assay. Cell viability is calculated as a percentage of the viable
cells in the vehicle treated group. The data are expressed as mean values ± SEM for three to four separate experiments with HBEpC from two
donors. *p< 0.05, **p< 0.01; compared with the values of control.
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HBEpC
Furthermore, we examined the effect of 25-HC on the re-
lease of IL-6 and IL-1β, which have been reported to be
released from airway epithelial cells after various types of
stimulation [12,22]. 25-HC significantly augmented the
release of IL-6, but not that of IL-1β from HBEpC
(Figure 2A-B).
Involvement of NF-κB and mitogen-actiated protein
kinase (p38, MEK1/2, JNK) signalling pathways in
25-HC-stimulated IL-8 release
To explore the mechanism of the 25-HC-augmented IL-8
release in the HBEpC, the effects of 25-HC on NF-κB and
JNK signalling pathways were evaluated. Treatment with25-HC caused a small but significant increase in the NF-κB
DNA binding activity after 30 min and 60 min (Figure 3A).
Furthermore, pretreatment with a NF-κB inhibitor, caffeic
acid phenethyl ester (CAPE), an inhibitor of nuclear factor
kappa-B alpha (IκBα) inhibitor, BAY 11–7085 and an in-
hibitor of nuclear factor kappa-B kinase-2 (IKK-2) inhibitor,
SC-514 dose-dependently inhibited the 25-HC-augmented
IL-8 release in the cells without affecting the cell viability
(Figure 3B-D, Additional file 1: Figure S1A-C).
Concerning the phosphorylated c-Jun, 10 μM 25-HC sig-
nificantly enhanced phosphorylated c-Jun translocation into
the nucleus (Figure 4A). Pre-treatment with a JNK inhibi-
tory peptide, L-JNKi1 significantly inhibited the IL-8 release
augmented by the incubation with an agonist of TLR3, poly


























Figure 2 Effect of 25-HC on other cytokines release in HBEpC. Cells were treated with various concentrations of 25-HC. After 24 h,
supernatants were harvested and assayed for IL-6 (A) and IL-1β (B) using a Cytometric Bead Array kit. The data are expressed as mean
values ± SEM for three to four separate experiments with HBEpC from two donors. *p< 0.05, **p< 0.01, compared with the values of control.
BAY= BAY 11–7085.
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25-HC-augmented IL-8 release (Figure 4B).
Furthermore, we examined the involvement of P38
mitogen-actiated protein kinase (MAPK) or MEK/ERK1/2
pathway in this mechanism. However, neither a p38 MAPK
inhibitor, SB203580, nor a MEK1/2 inhibitor, U0126,A
C













































Figure 3 Involvement of NF-κB signalling pathways in 25-HC-augmen
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Figure 4 Involvement of MAPK (p38, MEK1/2, JNK/AP-1) signalling pathways in 25-HC-augmented IL-8 release. (A) Cells were treated
with 10 μM 25-HC or vehicle. At various time points, the nuclear fraction of the cell lysates was obtained. Effect of 25-HC on translocation of
phosphorylated c-Jun into the nucleus. Translocation of the phosphorylated c-Jun into the nucleus was evaluated by immunoblotting. Each band
intensity was assessed by densitometry. Relative intensity was calculated by dividing the phosphorylated c-Jun band intensity by each
appropriate lamin A/C band intensity. The data are expressed as mean values ± SEM for three to seven separate experiments with HBEpC from
three donors. (B-D) Effect of c-Jun N-terminal kinase (JNK), p38 Mitogen-activated protein kinase (MAPK) or mitogenic extracellular kinase (MEK)1/
2 inhibitor on 25-HC-augmented IL-8 release in HBEpC. Cells were treated with 10 μM 25-HC or vehicle in the presence of a JNK inhibitory
peptide, L-JNKi1 (B), a p38 MAPK inhibitor, SB203580 (C) or a MEK1/2 inhibitor, U0126 (D). After 24 h, the supernatants were assayed for IL-8 by
ELISA. *p< 0.05, **p< 0.01, compared with the values of control at 0 min or the values of vehicle-treated cells. +++p< 0.01, compared with the
values of 25-HC-treated control cells. The data are expressed as mean values ± SEM for three to four separate experiments with HBEpC from two
donors. pcJun = phosphorylated c-Jun. N.S. = not significant.
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To examine the effect of 25-HC on the response of
TLR3 in airway epithelial cells, we investigated the effect
of 25-HC on the release of IL-8 from the poly(I:C)-treated
HBEpC. 25-HC significantly increased the release of IL-8
from the 10 μg/ml poly(I:C)-treated cells in a time- and
concentration-dependent manner (Figure 5A-B).
Effect of NF-kB on 25-HC-augmented IL-8 release in poly
(I:C)-treated cells
NF-κB pathway has been also reported to be involved in
the signal pathway after the stimulation of TLR3 [13], and
this was confirmed using a NF-κB inhibitor, CAPE. Pre-
treatment with CAPE significantly decreased the IL-8
release in poly(I:C)-treated cells (Figure 6A). Pretreatment
with CAPE slightly but significantly decreased the cell via-
bility in poly(I:C)-treated cells at 0.1 μM , however thiseffect was small and the decreased cell viability was 78.3%
(Additional file 1: Figure S2A). To elucidate the involve-
ment of the NF-κB pathway in the mechanism of the 25-
HC-augmented IL-8 release in the TLR3 stimulated cells,
we examine the effect of NF-κB inhibitors. Pretreatment
with a NF-κB inhibitor, CAPE, an IκBα inhibitor, BAY
11–7085 or an IKK-2 inhibitor, SC-514 significantly inhib-
ited the 25-HC-augmented IL-8 release in poly(I:C)-treated
cells without affecting the cell viability (Figure 6B-D,
Additional file 1: Figure S2B-D).
Effect of 25-HC on interferon regulatory factor 3 (IRF3)
and poly(I:C)-induced IFN-β release from HBEpC
To explore the effect of 25-HC on IRF3 signalling, which
is another crucial TLR3 signal pathway that induces the
release of IFNs, we investigated the effect of 25-HC on
the translocation of IRF-3 into the nucleus and the re-






































































Figure 5 Effect of 25-HC on poly(I:C)-augmented IL-8 release
from HBEpC. (A) Cells were treated with 10 μM 25-HC or vehicle 15
min prior to the treatment with 10 μg/ml poly(I:C). At various time
points after the incubation, supernatants were harvested and
assayed for IL-8. (B) Cells were treated with various concentrations
of 25-HC or vehicle 15 min prior to the treatment with 10 μg/ml
poly(I:C). After 24 h, supernatants were harvested and assayed for
IL-8. The data are expressed as mean values ± SEM for three to four
separate experiments with HBEpC from two donors. *p< 0.05,
**p< 0.01, compared with the values of vehicle-treated cells.
+p< 0.05, ++p< 0.01, compared with the values of poly(I:C) or
25-HC-treated control cells.
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the nucleus after 30 min and 60 min (Figure 7A). 25-HC
alone did not affect the release of IFN-β, but pre-
treatment with 25-HC significantly increased the release
of IFN-β from the 10 μg/ml poly(I:C)-treated cells
(Figure 7B).
Effect of 25-HC on the expression of TLR3 in
poly(I:C)-treated HBEpC
To examine the mechanism of the 25-HC-potentiated
IL-8 and IFN-β release in the poly(I:C)-treated cells, the
effect of 25-HC on the expression of TLR3 in the epithe-
lial cells was evaluated. However, treatment with 10 μM
25-HC or 10 μg/ml poly(I:C) alone or in combination
did not affect the expression of TLR3 (Figure 8).Discussion
In the present study, we demonstrated for the first time
that 25-HC stimulated the release of IL-8 and IL-6 from
primary human bronchial epithelial cells, mainly via NF-kB.
Furthermore, 25-HC potentiated the release of IL-8 and
IFN-β in TLR3 ligand, poly(I:C)-treated cells. These results
suggest that 25-HC may be involved in the neutrophilic air-
way inflammation via IL-8 and IL-6 release from airway
epithelial cells and also enhance the TLR3-mediated re-
sponse in airway epithelial cells (Figure 9).
In the present study, we demonstrated that 25-HC
increased IL-8 and IL-6 release from airway epithelial
cells, which was supported by previous reports on the
effect of 25-HC on IL-8 release in a human macrophage
lineage [5] and colon carcinoma cell line [23]. This result
may explain why the overproduction of 25-HC was cor-
related with the neutrophilic airway inflammation in
COPD in our previous report [11]. The effective concen-
tration of 25-HC in airway epithelial cells was higher
than 10-6 M, which was more than 100 times higher
than that in the sputum from COPD patients. However,
the concentration of 25-HC in sputum might be diluted
compared with that released in airways. Therefore, the
concentrations of 25-HC we used might potentiate cyto-
kines release from airway epithelial cells in COPD
patients. The augmenting effect of 25-HC on IL-8 re-
lease was more potent compared to that of the other
oxysterols, 22-HC and 27-HC. This result is consistent
with those of previous reports on monocyte-derived
macrophages and porcine retinal pigment epithelial cells
[24,25]. In the present study, the inducing effect of 25-HC
on IL-8 release was much weaker than that of poly(I:C),
suggesting that 25-HC might be an immune modulator
rather than an immune stimulator in airway epithelial
cells. However, the amount of IL-8 release in 25-HC-
treated airway epithelial cells was not largely different
from that in monocytes [10], suggesting that 25-HC might
cause the same degree of cellular response in airway epi-
thelial cells as in monocytes/macrophages, which have
been thought to be the major target cells of oxysterols.
Concerning the effect on cytotoxicity, 25-HC was less
cytotoxic compared with 22-HC and 27-HC in airway epi-
thelial cells. In the present study, the decrease of cell via-
bility induced by the treatment with oxysterols was likely
associated with the increased IL-8 release. Previous
reports demonstrated that oxysterols, including 25-HC,
induced IL-8 secretion in parallel with the induction of
cell death in monocyte/macrophages [10,24], but the rela-
tionship between oxysterols-induced IL-8 secretion and
cell death remains unclear. Further studies are needed to
clarify this point.
Oxysterols, including 25-HC, have been reported to be
ligands of liver X receptors, which regulate cholesterol
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Figure 6 Effect of NF-κB inhibitors on 25-HC-augmented IL-8 release in poly(I:C)-treated cells. (A) Effect of a NF-κB inhibitor, CAPE on poly
(I:C)-augmented IL-8 release in HBEpC. Cells were treated with various concentrations of CAPE 30 min prior to the treatment with 10 μg/ml
poly(I:C). After 24 h, supernatants were harvested and assayed for IL-8. (B-D) Effect of NF-κB inhibitors on 25-HC-augmented IL-8 release in
poly(I:C)-treated cells. Various concentrations of a NF-κB inhibitor, CAPE (B), an IκBα inhibitor, BAY 11–7085 (C) or an IKK-2 inhibitor, SC-514 (D)
were added before 10 μM 25-HC treatment, and the cells were then cultured in the presence of 10 μg/ml poly(I:C). After 24 h, supernatants were
harvested and assayed for IL-8. The data are expressed as mean values ± SEM for three to four separate experiments with HBEpC from two
donors. BAY= BAY 11–7085. N.S. = not significant.
Koarai et al. Respiratory Research 2012, 13:63 Page 8 of 11
http://respiratory-research.com/content/13/1/63receptor agonists, GW3965 and TO901317 did not aug-
ment IL-8 release and the treatment with TO901317 at
10-6 M inhibited the basal release of IL-8, which is in-
consistent with the augmenting effect of oxysterols on
IL-8 release in airway epithelial cells. However, this
discrepancy may be explained by a previous report,
which demonstrated that oxysterols induce the expres-
sion of inflammatory markers through liver X receptor-
independent mechanisms [18]. In the present study, we
also demonstrated the augmenting effect of 25-HC on
the poly(I:C)-induced IL-8 release in airway epithelial
cells. However, several reports have demonstrated the
inhibitory effect of oxysterols on the LPS-stimulated IL-1-
like activity and inflammatory response in murine macro-
phages via liver X receptors [27,28]. This discrepancy is
probably due to the different design of the experiments. In
the present study, the duration of the pre-treatment with
oxsterols was only 15 min before TLR3 ligand stimulation,
but that of the previous studies that demonstrated an in-
hibitory effect was more than 1 h; in most studies, 18–22
h incubation was followed by LPS stimulation. However, itremains unclear whether the stimulation of 25-HC in the
release of IL-8 is via any receptors except liver X recep-
tors, or indirect effects such as producing oxidative stress
by 25-HC [5,9,18,25]. Further studies are needed to clarify
these mechanisms.
Although the signaling pathways of 25-HC-augmented
IL-8 release remain poorly understood in airway epithe-
lial cells, it could be expected that MAPK (JNK, ERK
and p38) signal pathway is involved in the mechanism,
because it has been reported that 25-HC enhanced
MAPK (JNK, ERK and p38) phosphorylation [5,9,29]
and ERK inhibitor inhibited 7β-HC-induced IL-8 release
[10] in a human monocyte/macrophage lineage. In air-
way epithelial cells, these MAPKs are also activated by
various stimulations, leading to IL-8 release via a differ-
ent stimulus-dependent MAPK signaling [30,31]. How-
ever, in our present study, the 25-HC-induced IL-8
release in airway epithelial cells was not reduced by
treatment with a p38 MAPK inhibitor, SB203580, an
ERK inhibitor, U0126, or a JNK inhibitory peptide,
















































Figure 7 Effect of 25-HC on Interferon regulatory factor 3 (IRF3)
and poly(I:C)-induced IFN-β release from HBEpC. (A) Effect of
25-HC on translocation of IRF3 into the nucleus. Cells were treated
with 10 μM 25-HC or vehicle. At various time points, the nuclear
fraction of the cell lysates was obtained. Translocation of IRF3 into
the nucleus was evaluated by immunoblotting. Each band intensity
was assessed by densitometry. Relative intensity was calculated by
dividing the IRF3 band intensity by each appropriate lamin A/C
band intensity. (B) Effect of 25-HC on poly(I:C)-augmented IFN-β
release in HBEpC. Cells were treated with 10 μM 25-HC or vehicle in
the presence of 10 μg/ml poly(I:C). After 24 h, the supernatants were
assayed for IFN-β by ELISA. *p< 0.05, **p< 0.01, compared with the
values of control at 0 min. The data are expressed as mean
values ± SEM for four separate experiments with HBEpC from two
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Figure 8 Effect of 25-HC on TLR3 expression in poly(I:C)-treated
primary HBEpC. Cells were treated with 10 μM 25-HC or vehicle in
the presence of 10 μg/ml poly(I:C). After 24 h, the whole cell lysates
were obtained. The expression of TLR3 was evaluated by
immunoblotting. Each band intensity was assessed by densitometry.
Relative intensity was calculated by dividing the TLR3 band intensity
by each appropriate β-actin band intensity. The data are expressed
as mean values ± SEM for four separate experiments with HBEpC
from two donors. **p< 0.01, compared with the values of vehicle-
treated cells. +p< 0.05, compared with the values of each group.
N.S. = not significant.
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http://respiratory-research.com/content/13/1/63difference between monocytes/macrophages and airway
epithelial cells in their requirements for MAPK in the
25-HC–mediated signaling pathway. This may reflect
cell type- or stimulus-dependent differences in the role
of MAPK in IL-8 release. The mechanistic differences
between these cells in the 25-HC-mediated signaling
pathways should be further elucidated.In the present study, we demonstrated the involvement
of the signalling pathways of NF-κB in the 25-HC-induced
IL-8 release in human bronchial epithelial cells. This result
is consistent with a previous report which demonstrated
that a NF-κB inhibitor diminished oxysterol-induced cyto-
kine stimulation in THP-1 cells [9].
The augmented response of TLR3 in airway epithelial
cells could be involved in the exacerbation of airway dis-
ease including COPD [16,17,32]. We demonstrated for
the first time that 25-HC potentiates TLR3-mediated IL-8
and IFN-β release in airway epithelial cells. The mechan-
ism of the 25-HC-augmented TLR3-mediated IL-8 and
IFN-β release might be due to the potentiation of NF-κB
and IRF-3, which was suggested by the results that 25-HC
enhanced the NF-κB DNA binding activity and the trans-
location of IRF-3 into nucleus. In addition, there remains
a possibility that 25-HC stimulates TLR3 or the upper sig-
nal molecule including a Toll/IL-1 receptor domain-
containing adapter inducing IFNs (TRIF) for NF-κB and
IRF3 signalling pathways. However, 25-HC did not affect
the expression of TLR3. As another possibility, melanoma
differentiation-associated protein 5 and retinoic acid-
inducible gene 1 (RIG-I), which are cytosolic RIG-I-like






























Figure 9 Schematic representation of the effect of 25-HC on cytokine release and toll-like receptor 3 response. 25-HC potentiated the
release of IL-8 and IL-6 from HBEpC. 25-HC enhanced the NF-κB DNA binding activity and translocation of phosphorylated c-Jun into the nucleus.
A NF-κB inhibitor, CAPE, an IκBα inhibitor, BAY 11–7085, an IKK-2 inhibitor and SC-514, except a JNK inhibitory peptide, L-JNKi1 inhibited the
release of IL-8. Neither a P38 MAPK inhibitor, SB203580 nor a MEK1/2 inhibitor, U0126, affected the 25-HC-augmented IL-8 release. Agonists of
liver X receptors, GW3965 and TO901317, did not enhance IL-8 release, and TO901317 conversely inhibited IL-8 release. Concerning the effect of
25-HC on the TLR3 response, 25-HC potentiated the release of IL-8 stimulated by TLR3 ligand, poly(I:C), and the potentiation was inhibited by
CAPE, BAY 11–7085 and SC-514. 25-HC also potentiated the translocation of IRF3 into the nucleus and augmented the release of INF-β stimulated
by poly(I:C). However, treatment with 25-HC did not affect the expression of TLR3. These data suggest that 25-HC stimulates the release of IL-8
and IL-6 mainly via NF-κB and enhances the release of IL-8 and INF-β after stimulation of TLR3 in human airway epithelial cells. LXR = Liver X
receptor. BAY = BAY 11–8065.
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http://respiratory-research.com/content/13/1/63(I:C) [13], might be affected by 25-HC. More research
will be needed to precisely define these mechanisms.
Conclusions
We demonstrated that 25-HC stimulated the release of
IL-8 and IL-6, mainly via NF-κB pathway, and enhanced
the release of IL-8 and IFN-β after stimulation of TLR3 in
human airway epithelial cells. These results suggest that
25-HC may be involved in the neutrophilic airway inflam-
mation through the stimulating effect of IL-8 and IL-6
release, mainly via NF-κB pathway, and also potentiate the
TLR3-mediated response in airway epithelial cells.
Additional file
Additional file 1: Figure S1. Effect of NF-κB and MAPK inhibitors on
cell viability in 25-HC-treated HBEpC. Cells were treated with 10 μM 25-
HC or vehicle in the presence of an NF-kB inhibitor, caffeic acid
phenethyl ester (CAPE)(A), an IκBα inhibitor, BAY 11-7085 (B), an IKK-2
inhibitor, SC-514 (C), a JNK inhibitory peptide, L-JNKi1 (D), a p38 MAPK
inhibitor, SB203580 (E) or a MEK1/2 inhibitor, U0126 (F). After 24 h, the
cell viability was assessed by MTT assay. Cell viability is calculated as a
percentage of the viable cells in the vehicle treated group. The data are
expressed as mean values ± SEM for four separate experiments with
HBEpC from two donors. BAY = BAY 11-7085. N.S. = not significant. Figure
S2. Effect of NF-κB inhibitors on cell viability in 25-HC and poly(I:C)-
treated cells. (A) Effect of an NF-κB inhibitor, CAPE on cell viability in poly
(I:C)-treated HBEpC. Cells were treated with various concentrations of
CAPE 30 min prior to the treatment with 10 μg/ml poly(I:C). After 24 h,
cell viability was assessed by MTT assay. (B-D) Effect of the NF-kB inhibitor
on cell viability in 25-HC and poly(I:C)-treated cells. Variousconcentrations of the NF-κB inhibitor, CAPE (B), an IκBα inhibitor, BAY 11-
7085 (C) or an IKK-2 inhibitor, SC-514 (D) were added before 10 μM 25-
HC treatment, and the cells were then cultured in the presence of 10 μg/
ml poly(I:C). After 24 h, cell viability was assessed by MTT assay. Cell
viability is calculated as a percentage of the viable cells in the vehicle
treated group. The data are expressed as mean values ± SEM for three to
four separate experiments with HBEpC from two donors. BAY = BAY 11-
7085. N.S. = not significant.Abbreviations
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